menu
    • menu
    [{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Immunology","graph2":"Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Undisclosed","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Undisclosed","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Vimseltinib

    Menu

    Vimseltinib

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

                            Details : Vimseltinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

                            Details : Vimseltinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Full Approval for Deciphera’s ROMVIMZA™ in Treating TGCT

                            Details : Romvimza (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.

                            Product Name : Romvimza

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

                            Details : Vimseltinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 01, 2024

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Deciphera’s NDA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor

                            Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 15, 2024

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMA Accepts Deciphera’s MAA for Vimseltinib for Tenosynovial Giant Cell Tumor

                            Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib...

                            Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib i...

                            Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $143.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwrite...

                            Details : Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tum...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $143.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

                            Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 19, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth